AQR Capital Management LLC Makes New Investment in Omeros Co. (NASDAQ:OMER)

AQR Capital Management LLC bought a new position in shares of Omeros Co. (NASDAQ:OMER) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,800 shares of the biopharmaceutical company’s stock, valued at approximately $105,000.

A number of other hedge funds also recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in Omeros by 6.1% during the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock worth $454,000 after buying an additional 6,435 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares during the last quarter. Cypress Capital Group lifted its holdings in shares of Omeros by 40.0% during the 2nd quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 10,000 shares during the last quarter. Comerica Bank lifted its holdings in shares of Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after purchasing an additional 81,348 shares during the last quarter. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Trading Up 0.2 %

Shares of OMER opened at $4.15 on Friday. Omeros Co. has a 12 month low of $1.05 and a 12 month high of $5.68. The stock has a fifty day moving average price of $3.98 and a 200-day moving average price of $3.93.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($1.12) EPS for the quarter. As a group, analysts forecast that Omeros Co. will post -2.9 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Friday, August 16th.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.